Qiagen Expands NGS Portfolio with Oncology and Immunooncology Panels
The research panels can be performed using Qiagen’s GeneReader NGS system and other platforms, providing deep analysis of disease-related genomic mutations.
Read MorePosted by Steve Halasey | Dec 20, 2018 | Melanoma, Prostate |
The research panels can be performed using Qiagen’s GeneReader NGS system and other platforms, providing deep analysis of disease-related genomic mutations.
Read MorePosted by Steve Halasey | Dec 12, 2018 | Immunoassay |
The first such device to receive FDA clearance, Inova’s fecal extraction device provides significant workflow improvement to the laboratory.
Read MorePosted by Steve Halasey | Dec 4, 2018 | Research |
The partners’ study combines Neon’s personal neoantigen vaccine and Signatera’s circulating tumor DNA assay in a trial for metastatic non-small cell lung cancer.
Read MorePosted by Steve Halasey | Nov 28, 2018 | Cancer |
Genomics England names Congenica as its clinical decision support service partner for the delivery of the NHS genomic medicine service.
Read MorePosted by Steve Halasey | Nov 15, 2018 | Disease States, Infectious Diseases, Molecular Diagnostics, Sexually Transmitted Diseases |
Advanced testing methods promise improved patient outcomes and better protection of public health—with potential cost savings.
Read More